Akoya Biosciences, Inc.
AKYA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.15 | -0.09 | -0.08 |
| FCF Yield | -41.14% | -25.16% | -16.85% | -7.18% |
| EV / EBITDA | -5.00 | -4.81 | -6.17 | -14.01 |
| Quality | ||||
| ROIC | -45.88% | -38.87% | -46.51% | -22.66% |
| Gross Margin | 58.62% | 58.27% | 57.96% | 62.31% |
| Cash Conversion Ratio | 0.80 | 0.80 | 0.76 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.95% | 20.73% | 20.82% | 9.15% |
| Free Cash Flow Growth | 14.65% | 10.36% | -47.85% | -306.02% |
| Safety | ||||
| Net Debt / EBITDA | -1.95 | -0.06 | -0.03 | 2.28 |
| Interest Coverage | -4.48 | -6.58 | -14.54 | -11.95 |
| Efficiency | ||||
| Inventory Turnover | 1.39 | 2.26 | 2.17 | 2.30 |
| Cash Conversion Cycle | 229.66 | 119.41 | 92.18 | 55.34 |